References
- BayasAImproving adherence to injectable disease-modifying drugs in multiple sclerosisExpert Opin Drug Deliv201310328528723339371
- WingerchukDMCarterJLMultiple sclerosis: current and emerging disease-modifying therapies and treatment strategiesMayo Clin Proc201489222524024485135
- LugaresiARottoliMRPattiFFostering adherence to injectable disease-modifying therapies in multiple sclerosisExpert Review Neu-rother201414910291042
- TreadawayKCutterGSalterAFactors that influence adherence with disease-modifying therapy in MSJ Neurol2009256456857619444532
- PhillipsJTFoxEGraingerWTuccilloDLiuSDeykinAAn open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex(R) prefilled syringe in multiple sclerosis subjectsBMC Neurol20111112621999176
- DevonshireVArbizuTBorreBPatient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb studyBMC Neurol2010102820433746
- BayasAJappGFuldaUKallmannBAInjection devices in MS therapy: survey on neurologists, MS-nurses and patientsNervenheilkunde2010295762
- BrochetBLemaireGBeddiafAEpicure Study GReduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devicesRev Neurol20061626–773574016840982
- de SaJUrbanoGReisLAssessment of new application system in Portuguese patients with relapsing-remitting multiple sclerosisCurr Med Res Opin20102692237224220687777
- Verdun di CantognoERussellSSnowTUnderstanding and meeting injection device needs in multiple sclerosis: a survey of patient attitudes and practicesPatient Prefer Adherence2011517318021573048
- D‘ArcyCThomasDStonemanDParkesLPatient assessment of an electronic device for subcutaneous self-injection of interferon beta-1a for multiple sclerosis: an observational study in the UK and IrelandPatient Prefer Adherence20126556122298944
- KohlmannTWangCLipinskiJThe impact of a patient support program for multiple sclerosis on patient satisfaction and subjective health statusJ Neurosci Nurs2013453E3E1423636073
- PozzilliCSchweikertBEcariUOentrichWBuggeJPQuality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus studyJ Neurol2012259112319232822527232
- PozzilliCSchweikertBEcariUOentrichWBetaPlus Study groupSupportive strategies to improve adherence to IFN beta-1b in multiple sclerosis – results of the betaPlus observational cohort studyJ Neurol Sci20113071–212012621636099
- LamplCNaglSArnasonBEfficacy and safety of interferon beta-1b sc in older RRMS patients – a posthoc analysis of the BEYOND studyJ Neurol201326071838184523504050
- HuppertsRBeckerVFriedrichJMultiple sclerosis patients treated with intramuscular IFN-beta-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfactionExpert Opin Drug Deliv2015121152525430947
- LugaresiADurastantiVGasperiniCSafety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa studyClin Neuropharmacol200831316717218520983
- ZettlUKBauer-SteinhusenUGlaserTHechenbichlerKLimmrothVStudyGEvaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort studyBMC Neurol20131311724011220
- WHOAdherence to Long-Term Therapies – Evidence for ActionGenevaWorld Health Organization200392 4 154599 2
- OsterbergLBlaschkeTAdherence to medicationNew Engl J Med2005353548749716079372
- LugaresiAFlorioCBrescia-MorraVPatient adherence to and tolerability of self-administered interferon beta-1a using an electronic autoinjection device: a multicentre, open-label, phase IV studyBMC Neurol201212722390218